149 results
Page 3 of 8
8-K
EX-99.1
gqdia9 hnfomlvpxbg8
11 Jan 21
Karyopharm Announces Preliminary Unaudited Fourth Quarter and Full Year 2020 Total Revenues and Provides Commercial Update
8:06am
8-K
syxilvyeiw i4au8i
11 Jan 21
Karyopharm Announces Preliminary Unaudited Fourth Quarter and Full Year 2020 Total Revenues and Provides Commercial Update
8:06am
8-K
EX-99.1
6kxu88u3s8h9o
18 Dec 20
Karyopharm Announces FDA Approval of XPOVIO® (Selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Therapy
11:58am
8-K
EX-99.2
buhcc17yvlwhe31x
2 Nov 20
Karyopharm Reports Third Quarter 2020 Financial Results and Highlights Recent Company Progress
4:11pm
8-K
EX-99.1
jc8e8ub9q5b9 3wt
2 Nov 20
Karyopharm Reports Third Quarter 2020 Financial Results and Highlights Recent Company Progress
4:11pm
8-K
EX-99.1
pv5svinh jbh
4 Aug 20
Karyopharm Reports Second Quarter 2020 Financial Results and Highlights Recent Company Progress
7:13am
8-K
zez0uwq bn
14 Jul 20
Karyopharm Announces Preliminary Unaudited Second Quarter
7:08am
8-K
EX-99.1
d5z1o uqq7upl4py3
14 Jul 20
Karyopharm Announces Preliminary Unaudited Second Quarter
7:08am
8-K
EX-99.1
ukszfgocwly
22 Jun 20
Karyopharm Announces FDA Approval of XPOVIO® (selinexor) for the Treatment of
4:34pm
8-K
ydf05wcs
22 Jun 20
Karyopharm Announces FDA Approval of XPOVIO® (selinexor) for the Treatment of
4:34pm
424B5
om9wqtm u93azk5
5 May 20
Prospectus supplement for primary offering
5:05pm
8-K
EX-99.1
9svwn
4 Mar 20
Karyopharm Therapeutics Announces Pricing of Public Offering of Common Stock
4:22pm
424B5
8zwcg2fxc6v5rix2
4 Mar 20
Prospectus supplement for primary offering
4:15pm
424B5
qjcj0 9blpumueae13
2 Mar 20
Prospectus supplement for primary offering
4:21pm
8-K
EX-99.1
4ku858 xj2jmrj2p
2 Mar 20
Other Events
7:05am
S-3ASR
tvgm5s33pa9sg
26 Feb 20
Automatic shelf registration
8:35am